Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885464 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
A Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia, sponsored by Beam Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 10
- Study locations
NCT05885464: Active Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia, sponsored by Beam Therapeutics.
NCT05885464 is a Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia that is active but no longer recruiting, run by Beam Therapeutics. The registered enrollment target is 5 participants, below the 192-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05885464, a Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Beam Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Conditions Studied
Interventions
- BIOLOGICAL BEAM-201
Study Locations (10)
California
- Stanford University School of Medicine - Stanford
Colorado
- Colorado Blood Cancer Institute - Denver
Illinois
- University of Chicago - Chicago
Kansas
- The University of Kansas Cancer Center - Fairway
Massachusetts
- Dana Farber and Boston Children's Hospital - Boston
Ohio
- Cleveland Clinic- Taussig Cancer Center - Cleveland
Oregon
- OHSU Knight Cancer Institute Hematology Oncology - Portland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05885464 still lists
NCT05885464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 192-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Lymphoblastic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which BEAM-201 is the first listed.
NCT05885464 lists 10 locations in 10 states (California, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT05885464 about?
NCT05885464 is a clinical study titled "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)". This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to...
What is the current status of trial NCT05885464?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-05-25. Estimated completion is 2026-12.
What conditions does trial NCT05885464 study?
This clinical trial studies the following conditions: Lymphoblastic Lymphoma, Lymphoblastic Leukemia, T-Cell Lymphoblastic Leukemia/Lymphoma.
What interventions are being tested in trial NCT05885464?
The interventions under investigation include: BEAM-201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05885464?
This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885464 being conducted?
This trial has 10 study locations across California, Colorado, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05885464's enrollment target sits among peer trials
5 22nd of 21 the lowest of 21 other Lymphoblastic Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoblastic Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
RECRUITING · Phase 1
-
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
RECRUITING · Phase 1
-
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
RECRUITING · Phase 2
-
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
RECRUITING · NA
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI